The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

In a groundbreaking development for HIV prevention, the efficacy and safety of a six-monthly injection containing the antiretroviral drug lenacapavir have been confirmed through two pivotal studies.

Given recent approvals and a promising pipeline, new biomedical HIV prevention tools for women have the potential to ...

Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...

a drug used to treat type 2 diabetes, could help deplete the viral reservoir and eliminate it entirely in people living with HIV who receive antiretroviral ... Potential Link Between DNA Markers ...

In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...

Anemia prevalence was high in adult patients with HIV infection on HAART, with female sex, older age, and nonsuppressed viral load status identified as significant predictors.

The 40th annual AIDS Walk Los Angeles will take place Sunday in a very different world than when it first started.

As with other drugs, Biktarvy can cause side effects, such as diarrhea, nausea, and headache. For a general overview of Biktarvy, including details about what it’s used for, see this article.

Drug safety relates to the potential for adverse effects related to the administration of drugs. Efforts to establish the safely profile of drugs begin early in their development, with in vitro ...